-Genetics Boosted by Successful Treatment 2000-04-27Posted by clype in Discovery, Health, Science.
The controversial medical field of gene therapy has received a boost with the successful treatment of a ‘gene disorder’.
Two infants, aged 8 and 11 months, received new genetic material to combat a life-threatening disease called ‘Severe Combined Immunodeficiency’ (‘S.C.I.D.’).
Usually, patients with ‘S.C.I.D.’ are forced to live in tightly-controlled, sterile ‘bubbles’ to avoid threats to their non-existent immune systems.
A ‘bone marrow transplant’ is the conventional treatment for such patients. But the two treated children have shown ‘striking’ improvements and now live normally after their novel therapy.
Gene therapy trials in the U.S.A. have attracted much criticism over fears that patients were being harmed by the experimental treatments.
‘S.C.I.D.’ is caused when a defective copy of a gene on the ‘X-chromosome’ is inherited.
The corrupted gene means crucial components of the immune system do not develop and ‘S.C.I.D.’ patients are left fatally vulnerable to even slight infections such as a cold sore or common childhood diseases like chicken pox.
Scientists at the ‘Hospital Necker’ in Paris, France, began the therapy by taking bone marrow from the patients and sorting out a set of blood ‘stem cells’ from the marrow.
The cells were infected with a ‘retrovirus’ carrying the correct, replacement gene. After three days of repeated infection, the scientists transplanted the cells back into the patients.
As early as 15 days later, the team detected new cells bearing the correct version of the gene, along with rising numbers of fully functional and diverse immune cells.
Currently, the two patients have immune cell counts similar to healthy children of their age. The scientists also tested the patients’ newly-developed immune systems with ‘tetanus’, ‘diphtheria’, and ‘polio’ vaccinations, and found that the infants produced the correct ‘antibodies’ for each.
The infants’ return to a normal immune system has lasted over 11 months without side effects, says study co-author Mr.Alain Fischer. They are no longer in protective isolation and both live at home without any treatment.
A third patient is experiencing similar progress four months after the ‘gene transfer’.
Ideally, Mr.Fischer says, the children will be monitored for the rest of their lives, both to ensure their continued health and to monitor the long-term success of the therapy.
Secret of success
Mr.Fischer believes that the key to the therapy’s success lies ‘not in the technique, but in the disease itself.’
In the ‘S.C.I.D.’ cases, cells with the normal gene seem to enjoy a significant selective advantage, multiplying rapidly until their numbers overwhelm their mutated cousins. Mr.Fischer said:
‘This means that even a poorly efficient gene therapy technique — one that only introduces a few cells with the right gene– may work as a treatment,’